Ardena Acquires Catalent's Somerset, New Jersey Drug Product Facility

Codis Acquires Catalent’s Nottingham (UK) Facility

July 6, 2026

Healthcare Services

Codis has agreed to acquire Catalent Pharma Solutions’ spray-drying and oral solid dose facility in Nottingham, United Kingdom. The deal is expected to close in Q3 2026 (subject to customary conditions) and will add oral solid dose (OSD) development and small-scale commercial manufacturing to Codis’ existing large-scale commercial spray-drying site in Haverhill.

Novo Holdings Acquires Catalent for $16.5 Billion

December 18, 2024

Healthcare Services

Novo Holdings A/S agreed to acquire Catalent, Inc. in an all-cash transaction valued at approximately $16.5 billion ($63.50 per share). The deal was later completed, and Catalent became a private company under Novo Holdings ownership; Novo Nordisk subsequently acquired Catalent’s three fill-finish sites in Italy, Indiana (USA), and Belgium.

Ardena (GHO Capital Portfolio) Acquires Idifarma from Suanfarma and Sodena

September 2, 2021

Healthcare Services

Ardena, a GHO Capital-backed specialist pharmaceutical CDMO, has acquired Idifarma from Suanfarma and Sodena. The deal expands Ardena's European footprint and adds Idifarma's spray drying technology and high-potency drug capabilities at its Pamplona site, supporting Ardena's integrated end-to-end CDMO strategy.

Catalent Acquires Bettera Brands from Highlander Partners for $1 Billion

August 30, 2021

Food & Beverage

Catalent, Inc. agreed to acquire Bettera Holdings, LLC (Bettera Brands) from Highlander Partners for $1 billion. The acquisition expands Catalent's consumer health and nutraceutical manufacturing capabilities—adding Bettera's gummy, soft chew, and lozenge production capacity and approximately 500 employees across four U.S. facilities.

LGM Pharma Acquires Nexgen Pharma's Drug Product CDMO Business

July 23, 2020

Pharmaceuticals

LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, expanding LGM's CDMO capabilities and U.S.-based manufacturing footprint. Financial support for the transaction was provided by private equity firm New Harbor Capital; Nexgen Pharma sold its pharmaceutical CDMO unit to allow the company to focus on other healthcare segments.

GHO Capital Acquires Ardena, a European Early‑Stage CDMO

January 9, 2020

Pharmaceuticals

GHO Capital Partners LLP has acquired Ardena, a Belgium‑headquartered contract development and manufacturing organisation (CDMO) focused on early‑phase drug development, from Mentha Capital and existing management. GHO will partner with Ardena's management to accelerate international growth, broaden the company’s service offering and build a fully integrated early‑stage CDMO platform through organic and inorganic expansion.